betway必威登陆网址 (betway.com )学报››2023,Vol. 44››Issue (2): 110-115.DOI:10.3969/j.issn.2097-0005.2023.02.006
收稿日期:
2022-09-21出版日期:
2023-02-25发布日期:
2023-04-15通讯作者:
张云香作者简介:
侯倩,硕士,主治医师,研究方向:肿瘤病理, E-mail:houqian382@126.com。基金资助:
Qian HOU(), Yuping ZHANG, Hui WANG, Yunxiang ZHANG(
)
Received:
2022-09-21Online:
2023-02-25Published:
2023-04-15Contact:
Yunxiang ZHANG摘要:
目的研究趋化因子C?X?C基元受体6(chemokine C?X?C motif receptor 6, CXCR6)的表达与非小细胞肺癌(non‐small cell lung cancer, NSCLC)临床病理特征的关系,并探讨CXCR6表达、CD4+T细胞和CD8+T细胞浸润在NSCLC转移中的作用,为NSCLC发生、转移和预后判断提供依据。方法采用免疫组织化学法检测122例NSCLC原发灶、47例相应淋巴结转移灶及21例癌旁正常组织中CXCR6的表达情况及癌性间质中CD4+T细胞、CD8+T细胞的浸润情况。结果癌细胞中CXCR6的表达水平在Ⅲ ~ Ⅳ期、有淋巴结转移组高于Ⅰ ~ Ⅱ期、无淋巴结转移组;癌细胞中CXCR6的表达水平高于癌性间质及癌旁正常肺组织;原发灶CXCR6的表达水平高于淋巴结转移灶;癌组织中浸润的T细胞中CD4 、CD8表达水平均高于癌旁正常肺组织;CD4与癌细胞及癌性间质中CXCR6表达水平存在相关性。结论在NSCLC癌细胞中CXCR6高表达者容易发生淋巴结转移,CXCR6在转移中起着重要作用;癌细胞与癌性间质中CXCR6的表达在肿瘤免疫方面可能起着相反的作用。
侯倩, 张玉萍, 王慧, 张云香. CXCR6表达及CD4+、CD8+T细胞浸润在非小细胞肺癌转移中的价值[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(2): 110-115.
Qian HOU, Yuping ZHANG, Hui WANG, Yunxiang ZHANG. The value of CXCR6 expression and CD4+, CD8+T cell infiltration in metastasis of non-small cell lung cancer[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(2): 110-115.
临床特征 | n | 癌细胞 | 癌性间质 | ||||||
---|---|---|---|---|---|---|---|---|---|
低表达 | 高表达 | Z/χ2 | P | 低表达 | 高表达 | Z/χ2 | P | ||
性别 | 1.356 | 0.244 | 0.365 | 0.546 | |||||
男 | 68 | 22 | 46 | 51 | 17 | ||||
女 | 54 | 23 | 31 | 43 | 11 | ||||
年龄(岁) | 0.475 | 0.491 | 0.017 | 0.898 | |||||
≥ 60 | 71 | 28 | 43 | 55 | 16 | ||||
< 60 | 51 | 17 | 34 | 39 | 12 | ||||
组织类型 | 0.455 | 0.500 | 0.192 | 0.662 | |||||
鳞癌 | 31 | 13 | 18 | 23 | 8 | ||||
腺癌 | 91 | 32 | 59 | 71 | 20 | ||||
分化程度 | -2.188 | 0.029 | 1.215 | 0.545 | |||||
高分化 | 23 | 12 | 11 | 17 | 6 | ||||
中分化 | 59 | 23 | 36 | 48 | 11 | ||||
低分化 | 40 | 10 | 30 | 29 | 11 | ||||
临床分期 | 5.943 | 0.015 | 0.640 | 0.424 | |||||
Ⅰ ~ Ⅱ | 84 | 37 | 47 | 63 | 21 | ||||
Ⅲ ~ Ⅳ | 38 | 8 | 30 | 31 | 7 | ||||
淋巴结转移 | 12.958 | < 0.001 | 0.397 | 0.691 | |||||
有 | 47 | 8 | 39 | 40 | 7 | ||||
无 | 75 | 37 | 38 | 54 | 21 | ||||
吸烟史 | 0.303 | 0.582 | 0.043 | 0.835 | |||||
有 | 50 | 17 | 33 | 39 | 11 | ||||
无 | 72 | 28 | 44 | 55 | 17 | ||||
胸膜侵犯 | 0.014 | 0.905 | 1.447 | 0.229 | |||||
有 | 54 | 26 | 28 | 46 | 8 | ||||
无 | 68 | 32 | 36 | 52 | 16 |
表1NSCLS细胞和癌性间质细胞CXCR6的表达与NSCLC临床病理学特征的关系
临床特征 | n | 癌细胞 | 癌性间质 | ||||||
---|---|---|---|---|---|---|---|---|---|
低表达 | 高表达 | Z/χ2 | P | 低表达 | 高表达 | Z/χ2 | P | ||
性别 | 1.356 | 0.244 | 0.365 | 0.546 | |||||
男 | 68 | 22 | 46 | 51 | 17 | ||||
女 | 54 | 23 | 31 | 43 | 11 | ||||
年龄(岁) | 0.475 | 0.491 | 0.017 | 0.898 | |||||
≥ 60 | 71 | 28 | 43 | 55 | 16 | ||||
< 60 | 51 | 17 | 34 | 39 | 12 | ||||
组织类型 | 0.455 | 0.500 | 0.192 | 0.662 | |||||
鳞癌 | 31 | 13 | 18 | 23 | 8 | ||||
腺癌 | 91 | 32 | 59 | 71 | 20 | ||||
分化程度 | -2.188 | 0.029 | 1.215 | 0.545 | |||||
高分化 | 23 | 12 | 11 | 17 | 6 | ||||
中分化 | 59 | 23 | 36 | 48 | 11 | ||||
低分化 | 40 | 10 | 30 | 29 | 11 | ||||
临床分期 | 5.943 | 0.015 | 0.640 | 0.424 | |||||
Ⅰ ~ Ⅱ | 84 | 37 | 47 | 63 | 21 | ||||
Ⅲ ~ Ⅳ | 38 | 8 | 30 | 31 | 7 | ||||
淋巴结转移 | 12.958 | < 0.001 | 0.397 | 0.691 | |||||
有 | 47 | 8 | 39 | 40 | 7 | ||||
无 | 75 | 37 | 38 | 54 | 21 | ||||
吸烟史 | 0.303 | 0.582 | 0.043 | 0.835 | |||||
有 | 50 | 17 | 33 | 39 | 11 | ||||
无 | 72 | 28 | 44 | 55 | 17 | ||||
胸膜侵犯 | 0.014 | 0.905 | 1.447 | 0.229 | |||||
有 | 54 | 26 | 28 | 46 | 8 | ||||
无 | 68 | 32 | 36 | 52 | 16 |
组别 | n | 低表达 | 高表达 |
---|---|---|---|
癌细胞 | 122 | 45 | 77 |
癌性间质 | 122 | 94 | 28* |
癌旁正常肺组织 | 21 | 14 | 7* |
χ2 | 41.071 | ||
P | < 0.001 |
表2NSCLC癌细胞、癌性间质及癌旁正常 (肺组织中CXCR6的表达)
组别 | n | 低表达 | 高表达 |
---|---|---|---|
癌细胞 | 122 | 45 | 77 |
癌性间质 | 122 | 94 | 28* |
癌旁正常肺组织 | 21 | 14 | 7* |
χ2 | 41.071 | ||
P | < 0.001 |
临床特征 | n | CD4 | CD8 | ||||||
---|---|---|---|---|---|---|---|---|---|
低表达 | 高表达 | Z/χ2 | P | 低表达 | 高表达 | Z/χ2 | P | ||
性别 | 3.501 | 0.061 | 0.015 | 0.901 | |||||
男 | 68 | 43 | 25 | 12 | 56 | ||||
女 | 54 | 25 | 29 | 10 | 44 | ||||
年龄(岁) | 0.804 | 0.370 | 0.147 | 0.701 | |||||
≥ 60 | 71 | 42 | 29 | 12 | 59 | ||||
< 60 | 51 | 26 | 25 | 10 | 41 | ||||
组织类型 | 0.091 | 0.763 | 0.102 | 0.750 | |||||
鳞癌 | 31 | 18 | 13 | 5 | 26 | ||||
腺癌 | 91 | 50 | 41 | 17 | 74 | ||||
分化程度 | 2.103 | 0.036 | 0.025 | 0.980 | |||||
高分化 | 23 | 18 | 5 | 5 | 18 | ||||
中分化 | 59 | 31 | 28 | 9 | 50 | ||||
低分化 | 40 | 19 | 21 | 8 | 32 | ||||
临床分期 | 0.104 | 0.747 | 0.188 | 0.665 | |||||
Ⅰ ~ Ⅱ | 84 | 46 | 38 | 16 | 68 | ||||
Ⅲ ~ Ⅳ | 38 | 22 | 16 | 6 | 32 | ||||
淋巴结转移 | 2.029 | 0.154 | 0.053 | 0.818 | |||||
有 | 47 | 30 | 17 | 8 | 39 | ||||
无 | 75 | 38 | 37 | 14 | 61 | ||||
吸烟史 | 2.344 | 0.126 | 0.000 | 0.994 | |||||
有 | 50 | 32 | 18 | 9 | 41 | ||||
无 | 72 | 36 | 36 | 13 | 59 | ||||
胸膜侵犯 | 1.293 | 0.256 | 0.358 | 0.550 | |||||
有 | 54 | 27 | 27 | 11 | 43 | ||||
无 | 68 | 41 | 27 | 11 | 57 |
表3浸润T细胞中CD4及CD8表达水平与NSCLC临床病理学特征的关系
临床特征 | n | CD4 | CD8 | ||||||
---|---|---|---|---|---|---|---|---|---|
低表达 | 高表达 | Z/χ2 | P | 低表达 | 高表达 | Z/χ2 | P | ||
性别 | 3.501 | 0.061 | 0.015 | 0.901 | |||||
男 | 68 | 43 | 25 | 12 | 56 | ||||
女 | 54 | 25 | 29 | 10 | 44 | ||||
年龄(岁) | 0.804 | 0.370 | 0.147 | 0.701 | |||||
≥ 60 | 71 | 42 | 29 | 12 | 59 | ||||
< 60 | 51 | 26 | 25 | 10 | 41 | ||||
组织类型 | 0.091 | 0.763 | 0.102 | 0.750 | |||||
鳞癌 | 31 | 18 | 13 | 5 | 26 | ||||
腺癌 | 91 | 50 | 41 | 17 | 74 | ||||
分化程度 | 2.103 | 0.036 | 0.025 | 0.980 | |||||
高分化 | 23 | 18 | 5 | 5 | 18 | ||||
中分化 | 59 | 31 | 28 | 9 | 50 | ||||
低分化 | 40 | 19 | 21 | 8 | 32 | ||||
临床分期 | 0.104 | 0.747 | 0.188 | 0.665 | |||||
Ⅰ ~ Ⅱ | 84 | 46 | 38 | 16 | 68 | ||||
Ⅲ ~ Ⅳ | 38 | 22 | 16 | 6 | 32 | ||||
淋巴结转移 | 2.029 | 0.154 | 0.053 | 0.818 | |||||
有 | 47 | 30 | 17 | 8 | 39 | ||||
无 | 75 | 38 | 37 | 14 | 61 | ||||
吸烟史 | 2.344 | 0.126 | 0.000 | 0.994 | |||||
有 | 50 | 32 | 18 | 9 | 41 | ||||
无 | 72 | 36 | 36 | 13 | 59 | ||||
胸膜侵犯 | 1.293 | 0.256 | 0.358 | 0.550 | |||||
有 | 54 | 27 | 27 | 11 | 43 | ||||
无 | 68 | 41 | 27 | 11 | 57 |
组别 | n | CD4 | CD8 | ||||||
---|---|---|---|---|---|---|---|---|---|
低表达 | 高表达 | χ2 | P | 低表达 | 高表达 | χ2 | P | ||
NSCLC组织 | 122 | 68 | 54 | 4.725a | 0.030 | 22 | 100 | 11.907 | 0.001 |
癌旁正常肺组织 | 21 | 17 | 4 | 11 | 10 |
表4NSCLC与癌旁正常肺组织浸润的T细胞中CD4及CD8表达
组别 | n | CD4 | CD8 | ||||||
---|---|---|---|---|---|---|---|---|---|
低表达 | 高表达 | χ2 | P | 低表达 | 高表达 | χ2 | P | ||
NSCLC组织 | 122 | 68 | 54 | 4.725a | 0.030 | 22 | 100 | 11.907 | 0.001 |
癌旁正常肺组织 | 21 | 17 | 4 | 11 | 10 |
图1 CXCR6、CD4、CD8在NSCLS癌组织、癌旁组织及间质淋巴细胞的表达(免疫组化, × 200)A:CXCR6在鳞状细胞癌胞浆中的表达;B、E、K:CXCR6在腺癌细胞胞浆及间质淋巴细胞胞浆的表达;C:CXCR6在淋巴结转移灶癌细胞胞膜及胞浆中的表达;D:CXCR6在鳞状细胞癌胞浆及间质淋巴细胞胞浆中的表达;F:CXCR6在癌旁正常肺组织中浸润的少许淋巴细胞内表达;G、H:CD4在鳞状细胞癌及腺癌间质浸润的淋巴细胞胞膜中表达;I、J:CD8在鳞状细胞癌及腺癌间质浸润的淋巴细胞胞膜中表达;L:与K同一病例镜下同一区域CD4在癌性间质中浸润的淋巴细胞膜中表达。
1 | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209. |
2 | Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783. |
3 | Deng L, Chen N, Li Y, et al. CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer[J]. Biochim Biophys Acta, 2010, 1806(1): 42. |
4 | 许良中, 杨文涛. 免疫组织化学反应结果的判断标准[J]. 中国癌症杂志, 1996(4): 229. |
5 | Wang J, Lu Y, Wang J, et al. CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway[J]. Cancer Res, 2008, 68(24): 10367. |
6 | Hojo S, Koizumi K, Tsuneyama K, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer[J]. Cancer Res, 2007, 67(10): 4725. |
7 | Nakayama T, Hieshima K, Izawa D, et al. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues[J]. J Immunol, 2003, 170(3): 1136. |
8 | Morgan AJ, Guillen C, Symon FA, et al. Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease[J]. Clin Exp Allergy, 2005, 35(12): 1572. |
9 | Heydtmann M, Lalor PF, Eksteen JA, et al. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver[J]. J Immunol, 2005, 174(2): 1055. |
10 | Hattermann K, Gebhardt H, Krossa S, et al. Transmembrane chemokines act as receptors in a novel mechanism termed inverse signaling[J]. Elife, 2016, 5: e10820. |
11 | Hu W, Liu Y, Zhou W, et al. CXCL16 and CXCR6 are coexpressed in human lung cancerin vivoand mediate the invasion of lung cancer cell linesin vitro[J]. PLoS One, 2014, 9(6): e99056. |
12 | Lin S, Sun L, Hu J, et al. Chemokine C-X-C motif receptor 6 contributes to cell migration during hypoxia[J]. Cancer Lett, 2009, 279(1): 108. |
13 | Gooden MJ, Wiersma VR, Boerma A, et al. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity[J]. Br J Cancer, 2014, 110(6): 1535. |
14 | Matsushita K, Toiyama Y, Tanaka K, et al. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients[J]. Ann Surg Oncol, 2012, 19 : S518. |
15 | Cao Y, Zhang L, Kamimura Y, et al. B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin[J]. Cancer Res, 2011, 71(4): 1235. |
16 | Vazquez-Cintron EJ, Monu NR, Frey AB. Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+lymphocytes inactivates antitumor effector phase[J]. J Immunol, 2010, 185(12): 7133. |
17 | Day C, Patel R, Guillen C, et al. The chemokine CXCL16 is highly and constitutively expressed by human bronchial epithelial cells[J]. Exp Lung Res, 2009, 35(4): 272. |
18 | Sato T, Thorlacius H, Johnston B, et al. Role for CXCR6 in recruitment of activated CD8+lymphocytes to inflamed liver[J]. J Immunol, 2005, 174(1): 277. |
19 | Xu H, Xu W, Chu Y, et al. Involvement of up-regulated CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in endotoxin-induced lethal liver injury via regulation of T-cell recruitment and adhesion[J]. Infect Immun, 2005, 73(7): 4007. |
[1] | 龙赤荣, 张露, 彭上, 闵静婷, 李正红.嵌合抗原受体T细胞治疗结肠癌的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(9): 682-686. |
[2] | 张露, 赵乐乐, 解思凯, 李海鹏, 王俊杰, 李正红.嵌合抗原受体T细胞治疗女性高发恶性肿瘤的研究进展和挑战[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(8): 608-612. |
[3] | 李彬, 冯锋, 刘富垒.肿瘤切除手术诱发术后复发的机制及纠正策略研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(7): 535-540. |
[4] | 任巧雅, 李琳, 马虎.Keap1/Nrf2通路在非小细胞肺癌中的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(6): 466-471. |
[5] | 周海英, 郭冉, 赵聪, 吴培培, 陈卫东, 孙宗文.血清NLR、PLR与非小细胞肺癌预后相关性研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(2): 147-151. |
[6] | 周晓丽, 胡顺凤, 王欣.精准医学时代治疗外周T细胞淋巴瘤的新型药物研究进展[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(1): 1-9. |
[7] | 郑秋香, 赖佛宝, 陈志勇.程序性死亡受体‑1抑制剂联合化疗治疗晚期非小细胞肺癌[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(9): 692-696. |
[8] | 史丽雪, 曹文华.D⁃二聚体、CEA、SCC⁃Ag与非小细胞肺癌关系研究进展[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(5): 393-396. |
[9] | 刘蕾, 李小龙, 高英华, 郑家辉, 杨帆, 吴若晨, 张晓宇, 张树鹏.单形性亲上皮性肠道T细胞淋巴瘤临床病理分析[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(12): 932-937. |
[10] | 张岱, 李炫宗, 黄彩梅, 王琳琳.BIM缺失与非小细胞肺癌患者抗肿瘤治疗研究进展[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(10): 788-791. |
[11] | 孔令玉, 魏晓玉, 周行健, 刘靖, 李晶.食管鳞状细胞癌组织Gas6和Axl表达与CEA、SCC、CYFRA21-1的相关性[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(1): 2-6. |
[12] | 赵怡然, 朱建忠, 冯文静.骶孔占位:良性转移性平滑肌瘤1例[J]. betway必威登陆网址 (betway.com )学报, 2021, 42(6): 469-470. |
[13] | 张现莉.原发性肝细胞癌患者外周血中T细胞及NK细胞的水平变化和临床意义探讨[J]. betway必威登陆网址 (betway.com )学报, 2021, 42(4): 281-283. |
[14] | 袁绪龙, 赵嫚, 纪波, 穆玉恕.非小细胞肺癌患者血脂联合检测分析[J]. betway必威登陆网址 (betway.com )学报, 2021, 42(4): 267-269. |
[15] | 孙雯雯, 吴开祥, 李小龙, 张亚, 东野圣伊, 黄虎, 丁宝琪, 杨洪川, 王新立.实用免疫组化组织微阵列对照体系的构建及其蜡块、切片的制作方法[J]. betway必威登陆网址 (betway.com )学报, 2021, 42(3): 221-224. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||